Canaccord Genuity Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $10

Benzinga Newsdesk www.benzinga.com Neutral 57.2%

Neg 0% Neu 57.2% Pos 0%

Canaccord Genuity analyst Edward Nash initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Buy rating and announces Price Target of $10.